Literature DB >> 9111321

Heteromeric and homomeric interactions correlate with signaling activity and functional cooperativity of Smad3 and Smad4/DPC4.

R Y Wu1, Y Zhang, X H Feng, R Derynck.   

Abstract

Homologs of Drosophila Mad function as downstream mediators of the receptors for transforming growth factor beta (TGF-beta)-related factors. Two homologs, the receptor-associated Smad3 and the tumor suppressor Smad4/DPC4, synergize to induce ligand-independent TGF-beta activities and are essential mediators of the natural TGF-beta response. We now show that Smad3 and Smad4 associate in homomeric and heteromeric interactions, as assessed by yeast two-hybrid and coimmunoprecipitation analyses. Heteromeric interactions are mediated through the conserved C-terminal domains of Smad3 and Smad4. In Smad3, the homomeric interaction is mediated by the same domain. In contrast, the homomeric association of Smad4 requires both the N-terminal domain and the C-terminal domain, which by itself does not homomerize. Mutations that have been associated with impaired Mad activity in Drosophila or decreased tumor suppressor activity of Smad4/DPC4 in pancreas cancer, including a short C-terminal truncation and two point mutations in the conserved C-terminal domains, impair the ability of Smad3 and Smad4 to undergo homo- and heteromeric associations. Analyses of the biological activity of Smad3 and Smad4 and their mutants show that full signaling activity correlates with their ability to undergo efficient homo- and heteromeric interactions. Mutations that interfere with these interactions result in decreased signaling activity. Finally, we evaluated the ability of Smad3 or Smad4 to induce transcriptional activation in yeast. These results correlate the ability of individual Smads to homomerize with transcriptional activation and additionally with their biological activity in mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9111321      PMCID: PMC232101          DOI: 10.1128/MCB.17.5.2521

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  23 in total

1.  Specific interaction of type I receptors of the TGF-beta family with the immunophilin FKBP-12.

Authors:  T Wang; P K Donahoe; A S Zervos
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

2.  A WD-domain protein that is associated with and phosphorylated by the type II TGF-beta receptor.

Authors:  R H Chen; P J Miettinen; E M Maruoka; L Choy; R Derynck
Journal:  Nature       Date:  1995-10-12       Impact factor: 49.962

Review 3.  The TGF-beta superfamily: new members, new receptors, and new genetic tests of function in different organisms.

Authors:  D M Kingsley
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

4.  Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor.

Authors:  R Ebner; R H Chen; L Shum; S Lawler; T F Zioncheck; A Lee; A R Lopez; R Derynck
Journal:  Science       Date:  1993-05-28       Impact factor: 47.728

5.  Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex. Characterization of chimeric and truncated type I and type II receptors.

Authors:  X H Feng; E H Filvaroff; R Derynck
Journal:  J Biol Chem       Date:  1995-10-13       Impact factor: 5.157

6.  Mechanism of activation of the TGF-beta receptor.

Authors:  J L Wrana; L Attisano; R Wieser; F Ventura; J Massagué
Journal:  Nature       Date:  1994-08-04       Impact factor: 49.962

7.  Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster.

Authors:  J J Sekelsky; S J Newfeld; L A Raftery; E H Chartoff; W M Gelbart
Journal:  Genetics       Date:  1995-03       Impact factor: 4.562

Review 8.  TGF-beta-receptor-mediated signaling.

Authors:  R Derynck
Journal:  Trends Biochem Sci       Date:  1994-12       Impact factor: 13.807

9.  Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2.

Authors:  J Gyuris; E Golemis; H Chertkov; R Brent
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

10.  Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta.

Authors:  M R Keeton; S A Curriden; A J van Zonneveld; D J Loskutoff
Journal:  J Biol Chem       Date:  1991-12-05       Impact factor: 5.157

View more
  46 in total

1.  Regulation of Smad degradation and activity by Smurf2, an E3 ubiquitin ligase.

Authors:  Y Zhang; C Chang; D J Gehling; A Hemmati-Brivanlou; R Derynck
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

Review 2.  Transcriptional control by the TGF-beta/Smad signaling system.

Authors:  J Massagué; D Wotton
Journal:  EMBO J       Date:  2000-04-17       Impact factor: 11.598

3.  Smad3 recruits the anaphase-promoting complex for ubiquitination and degradation of SnoN.

Authors:  S L Stroschein; S Bonni; J L Wrana; K Luo
Journal:  Genes Dev       Date:  2001-11-01       Impact factor: 11.361

4.  Smads bind directly to the Jun family of AP-1 transcription factors.

Authors:  N T Liberati; M B Datto; J P Frederick; X Shen; C Wong; E M Rougier-Chapman; X F Wang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Smads orchestrate specific histone modifications and chromatin remodeling to activate transcription.

Authors:  Sarah Ross; Edwin Cheung; Thodoris G Petrakis; Michael Howell; W Lee Kraus; Caroline S Hill
Journal:  EMBO J       Date:  2006-09-21       Impact factor: 11.598

6.  Novel roles of Akt and mTOR in suppressing TGF-beta/ALK5-mediated Smad3 activation.

Authors:  Kyung Song; Hui Wang; Tracy L Krebs; David Danielpour
Journal:  EMBO J       Date:  2005-12-15       Impact factor: 11.598

7.  Determinants of specificity in TGF-beta signal transduction.

Authors:  Y G Chen; A Hata; R S Lo; D Wotton; Y Shi; N Pavletich; J Massagué
Journal:  Genes Dev       Date:  1998-07-15       Impact factor: 11.361

8.  Smad proteins exist as monomers in vivo and undergo homo- and hetero-oligomerization upon activation by serine/threonine kinase receptors.

Authors:  M Kawabata; H Inoue; A Hanyu; T Imamura; K Miyazono
Journal:  EMBO J       Date:  1998-07-15       Impact factor: 11.598

9.  Transcriptional activating activity of Smad4: roles of SMAD hetero-oligomerization and enhancement by an associating transactivator.

Authors:  T Shioda; R J Lechleider; S L Dunwoodie; H Li; T Yahata; M P de Caestecker; M H Fenner; A B Roberts; K J Isselbacher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein.

Authors:  J M Yingling; M B Datto; C Wong; J P Frederick; N T Liberati; X F Wang
Journal:  Mol Cell Biol       Date:  1997-12       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.